Qiagen (NYSE:QGEN – Get Free Report) and Atyr PHARMA (NASDAQ:ATYR – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.
Profitability
This table compares Qiagen and Atyr PHARMA’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Qiagen | 4.23% | 13.92% | 8.40% |
| Atyr PHARMA | N/A | -79.44% | -59.16% |
Insider & Institutional Ownership
70.0% of Qiagen shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Qiagen | $1.98 billion | 4.36 | $83.59 million | $0.36 | 108.06 |
| Atyr PHARMA | $235,000.00 | 1,425.23 | -$50.39 million | ($0.94) | -4.24 |
Qiagen has higher revenue and earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Qiagen has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Qiagen and Atyr PHARMA, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Qiagen | 0 | 7 | 3 | 0 | 2.30 |
| Atyr PHARMA | 0 | 0 | 6 | 1 | 3.14 |
Qiagen currently has a consensus target price of $47.71, suggesting a potential upside of 22.63%. Atyr PHARMA has a consensus target price of $18.60, suggesting a potential upside of 366.17%. Given Atyr PHARMA’s stronger consensus rating and higher probable upside, analysts plainly believe Atyr PHARMA is more favorable than Qiagen.
Summary
Qiagen beats Atyr PHARMA on 9 of the 15 factors compared between the two stocks.
About Qiagen
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
About Atyr PHARMA
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
